12 Health Care Stocks Moving In Thursday's After-Market Session

Benzinga · 03/20 21:06
Gainers
- Impact BioMedical (AMEX:IBO) stock moved upwards by 98.1% to $4.12 during Thursday's after-market session. The company's market cap stands at $47.3 million.
- Apogee Therapeutics (NASDAQ:APGE) shares increased by 10.7% to $44.69. The market value of their outstanding shares is at $2.5 billion.
- Intensity Therapeutics (NASDAQ:INTS) shares moved upwards by 9.32% to $2.11. The company's market cap stands at $32.0 million.
- Wellgistics Health (NASDAQ:WGRX) shares moved upwards by 8.52% to $5.14. The company's market cap stands at $266.9 million.
- Bluejay Diagnostics (NASDAQ:BJDX) shares rose 8.1% to $4.27. The market value of their outstanding shares is at $2.3 million.
- GlucoTrack (NASDAQ:GCTK) shares moved upwards by 6.79% to $0.44. The company's market cap stands at $4.5 million.
Losers
- TELA Bio (NASDAQ:TELA) shares decreased by 15.6% to $1.95 during Thursday's after-market session. The company's market cap stands at $76.8 million. As per the news, the Q4 earnings report came out today.
- Maravai LifeSciences (NASDAQ:MRVI) stock fell 11.67% to $2.12. The market value of their outstanding shares is at $304.5 million. As per the press release, Q4 earnings came out 2 days ago.
- Plus Therapeutics (NASDAQ:PSTV) shares declined by 9.56% to $1.23. The company's market cap stands at $7.2 million.
- Cyclo Therapeutics (NASDAQ:CYTH) shares decreased by 7.01% to $0.63. The company's market cap stands at $20.7 million.
- Eyenovia (NASDAQ:EYEN) stock declined by 6.95% to $1.34. The market value of their outstanding shares is at $2.8 million.
- OS Therapies (AMEX:OSTX) shares declined by 6.92% to $1.48. The market value of their outstanding shares is at $31.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.